Wordt geladen...
PRSS contributes to cetuximab resistance in colorectal cancer
Cetuximab improves the survival of patients with metastatic colorectal cancer. The main limitation is primary and secondary resistance, the underlying mechanism of which requires extensive investigation. We proved that PRSS expression levels are significantly negatively associated with the sensitivi...
Bewaard in:
| Gepubliceerd in: | Sci Adv |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Association for the Advancement of Science
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6938705/ https://ncbi.nlm.nih.gov/pubmed/31911942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aax5576 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|